News MSD taps Quotient for IBD drug targets in $2.2bn deal MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.
News AstraZeneca reportedly hit by serious cyberattack A hacking group claims to have broken into AstraZeneca's IT systems and stolen confidential data, which they are now offering for sale.
News Keytruda cleared for NHS use in early head and neck cancer MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer.
News Gilead buys autoimmune disease biotech Ouro for $2.2bn Gilead has agreed to buy Ouro and its T-cell engagers for autoimmune diseases in a $2.2bn deal that may also revive its alliance with Galapagos.
News Sanofi pays $180m for rights to Kali autoimmune drug Sanofi has licensed rights to Kali's trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.
News Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss Missing the primary endpoint in a phase 3 trial will not stop Pfizer from submitting Valneva-partnered Lyme disease vaccine for approval.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.